Literature DB >> 7459811

Reporting results of cancer treatment.

A B Miller, B Hoogstraten, M Staquet, A Winkler.   

Abstract

On the initiative of the World Health Organization, two meetings on the Standardization of Reporting Results of Cancer Treatment have been held with representatives and members of several organizations. Recommendations have been developed for standardized approaches to the recording of baseline data relating to the patient, the tumor, laboratory and radiologic data, the reporting of treatment, grading of acute and subacute toxicity, reporting of response, recurrence and disease-free interval, and reporting results of therapy. These recommendations, already endorsed by a number of organizations, are proposed for international acceptance and use to make it possible for investigators to compare validly their results with those of others.

Entities:  

Mesh:

Year:  1981        PMID: 7459811     DOI: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  1577 in total

1.  The role of neoadjuvant and adjuvant chemotherapy regimens consisting of different combinations of drugs in the treatment of advanced oral cancer.

Authors:  S Basu; M Khanra; B Dash; J Majumdar; J Biswas; P Chaudhuri
Journal:  Med Oncol       Date:  1999-09       Impact factor: 3.064

2.  Preoperative chemotherapy for advanced esophageal cancer and relation with histological effect.

Authors:  Y Hosoya; H Shibusawa; H Nagai; I Ueno; K Sakuma; T Nagashima; N Kobayashi; K Kanazawa
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

3.  Interstitial chemotherapy plus systemic chemotherapy for glioblastoma patients: improved survival in sequential studies.

Authors:  A Boiardi; A Silvani; A Pozzi; L Fariselli; G Broggi; A Salmaggi
Journal:  J Neurooncol       Date:  1999-01       Impact factor: 4.130

4.  Hamming clustering techniques for the identification of prognostic indices in patients with advanced head and neck cancer treated with radiation therapy.

Authors:  G Paoli; M Muselli; R Bellazzi; R Corvó; D Liberati; F Foppiano
Journal:  Med Biol Eng Comput       Date:  2000-09       Impact factor: 2.602

Review 5.  Assessment of response to therapy using conventional imaging.

Authors:  Sheila C Rankin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-03-27       Impact factor: 9.236

6.  Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside (MMPR), and leucovorin in patients with advanced cancer.

Authors:  A Hageboutros; G R Hudes; F Greene; F P LaCreta; J Brennan; P J O'Dwyer
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

7.  Prolonged infusion gemcitabine: a clinical phase I study at low- (300 mg/m2) and high-dose (875 mg/m2) levels.

Authors:  C F Pollera; A Ceribelli; M Crecco; C Oliva; F Calabresi
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

Review 8.  Treatment-related changes in glioblastoma: a review on the controversies in response assessment criteria and the concepts of true progression, pseudoprogression, pseudoresponse and radionecrosis.

Authors:  P D Delgado-López; E Riñones-Mena; E M Corrales-García
Journal:  Clin Transl Oncol       Date:  2017-12-07       Impact factor: 3.405

9.  A phase I trial of intraperitoneal recombinant interleukin 2 in patients with ovarian carcinoma.

Authors:  P B Chapman; J E Kolitz; T B Hakes; J L Gabrilove; K Welte; V J Merluzzi; A Engert; E C Bradley; M Konrad; R Mertelsmann
Journal:  Invest New Drugs       Date:  1988-09       Impact factor: 3.850

10.  Ifosfamide, mesna, and interferon-alpha2A combination chemoimmunotherapy in malignant mesothelioma: results of a single center in central anatolia.

Authors:  Mustafa Altinbas; Ozlem Er; Metin Ozkan; Hasan Senol Coskun; Inci Gulmez; Eyup Ekici; Bunyamin Kaplan; Bulent Eser; Mustafa Ozesmi
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.